Taiwan: Pharma at the Tipping Point
After many years of building up an impressive resource base, the industry is finally ready to take advantage of the wave of enthusiasm and interest surounding pharma and biotech that is sweeping the nation
PharmEssentia: The 30-Year Dream
A small company shows how it can play a major role in a relatively short time frame
Giddi Pharma: Putting the 'Special' into Specialty Pharma
How to achieve distribution diversification in a small market
Don't Judge a Book by its Cover (Or Its Title)
With a fiercely competitive spirit and grand ambitions that reach far beyond Taiwan, Standard is showing that it is far from the middle-of-the-road company its name implies
Patient Empowerment by Decision Making Literacy
The simpler the explanation of a disorder and its treatment, the better able a patient is to take proper care of himself
Taking Advantage of the Science Behind Marketing
Being strategic-and applying data tools effectively- will go along way in helping to produce analytics that drive sales
Gentle Collisions in Marketing
Healthcare marketing in today's post-recession economy is not about one-size-fits-all vehicles, but rather about bringing your prouct into consumers' lives in a series of personal, non-invasive ways
Emerging Stakeholders with Clout: The Press Power Behind ProPublica
The new investigative journalism organization recently took an in-depth look at pharma with its "Dollars for Docs" report. In return, Pharm Exec takes a look back at ProPublica
In Through the Out Door
The end of anther year is an appropriate time to highlight the march of time-and the transitions that accompany it
US Anti-Corruption Regulation Risks
Stepped-up enforcement of the Foreign Corrupt Practices Act requires enhanced global coordination of compliance
Adherence Equation: The Code is Cracked!
Putting science front-and-center in the design of patient adherence programs can lead to a better understanding of the commitment required to get patients to take their medicine
The Sum of All His Parts: Career Reflections of Europe's Chief Drug Regulator
Outgoing EMA Director Thomas Lonngren discusses a decade at the helm of Europe's top regulatory office
The Next Wave: Pharm Exec's 2011 Pipeline Report
42 of the best new drugs in development–or parked at the FDA
China 2020: Walled In No More
Pharma sets the pace for China's ambitious new innovation agenda
A New Twist in the Cost Curve
The strict regulatory divide between market authorization and price reimbursement iscrumbling in the US. Is industry prepared to adapt or challenge?
Is Euroland Following the US Disclosure Lead?
Cegedim survey documents whether European industry is ready for the challenge of new compliance and disclosure risks on promotional spend
Nicotine Addiction: What Lights Up the Field
Pharm Exec's Pipeline Report 2018
